ClinicalTrials.gg
TerminatedNCT00441584Updated Apr 5, 2017Results posted

The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

A Phase 3 interventional study of PegIntron (peginterferon alfa-2b) and Rebetol (ribavirin) in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
Subject accrual was prematurely terminated due slow enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
117
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
15th of 39
117 · median 99
Started
2005
with 7 others
Phase 3
22 of 40
none open now
Registered
17th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 15th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2005, is one of 22 in phase 3, and was the 17th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

This is an uncontrolled, non-randomized, open-label, multinational study designed to evaluate the efficacy and safety of PegIntron plus Rebetol in subjects with chronic hepatitis C. The study is designed to determine the proportion of chronic hepatitis C genotype 1 subjects who did not respond to previous treatment with Pegasys 180µg QW plus ribavirin, that will achieve sustained virological response (SVR) when treated with PegIntron plus Rebetol.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must demonstrate their willingness to participate in the study and comply with its procedures by signing a written .
  • Subject must be 18-70 years of age of either sex and of any race.
  • Subject must be diagnosed with chronic genotype 1 (confirmation by not required). (Liver function tests (LFTs) can be normal or elevated.)
  • Female subjects cannot be pregnant or breastfeeding and must be either , surgically sterile or using 2 methods of . While abstinence from sexual activity is the only certain method to prevent pregnancy, female patients of who are or who anticipate the possibility of becoming sexually active with a male partner must use a combination of the following 2 methods:

    • Contraceptive pill or intrauterine device (IUD) or depot hormonal preparation (ring, injection, implant), and
    • A barrier method of contraception such as diaphragm, sponge with spermicide, condom, or a method of birth control considered acceptable by the study physician.
  • Contraceptive measures will be reviewed with female subjects at each visit. Dual methods of contraception must be used for 6 months after treatment discontinuation.
  • Female subjects of childbearing potential must have a negative serum pregnancy test at screen phase and during the study.
  • Confirmation by the principal investigator or a sub-investigator that sexually active male subjects are practicing a method of contraception considered acceptable (vasectomy, condom plus spermicide, plus relationship with a female partner who practices an acceptable method of contraception). Contraception must be used during the treatment period and for seven months after the completion of therapy, including condom use by male subjects with pregnant partners.
  • Subject must be free of any disease that would interfere with study evaluations.
  • Subject must understand, be able to and agree to adhere to the dosing and visit schedules.
  • Compensated liver disease with the following minimum hematologic and biochemical criteria at the Day 1 visit within normal limits:

    • values equal to or greater than 12 g/dL for females and 13 g/dL for males
    • White blood cell (WBC) count equal to or greater than 3,000/cu mm
    • equal to or greater than 1,500/cu mm
    • count equal to or greater than 80,000/cu mm
    • Direct within normal limits
    • Indirect bilirubin within normal limits (unless non-hepatitis related factors such as Gilbert's disease explain an indirect bilirubin rise). In such cases indirect bilirubin should be less than or equal to 3.0 mg/dL (less than or equal to 51.3 µmol/L)
    • Albumin within normal limits
    • Serum creatinine within normal limits
    • Subject must be a non-responder, defined as having received and not having responded to a prior treatment consisting of one course of Pegasys 180 mcg QW in combination with ribavirin 1000-1200 mg daily, with or without amantadine, for a minimum of 12 weeks and:

      • Subject must be found to be hepatitis C virus (HCV)-ribonucleic acid (RNA) positive with less than a 2-log drop at 12 weeks of treatment, or
      • is polymerase chain reaction (PCR)-positive at End Of Treatment, whether End Of Treatment happened at week 48 or earlier
  • Subject must be off Pegasys/ribavirin at least 12 weeks prior to screen.
  • Subject must have had no other treatment with any interferon except Pegasys.
  • Subject must neither have received nor currently be on any other treatment for his chronic hepatitis C disease, except for amantadine.
  • When available, historical liver biopsy with pathology report of the subject must confirm that the histological diagnosis is consistent with chronic hepatitis C.
  • Subject must have a value of thyroid stimulating hormone within normal limits (whether euthyroid or requiring thyroid medications).
  • Antinuclear antibodies must be less than or equal to 1:320.
  • If abdominal imaging has been performed within 1 year prior to screen, it must not show evidence of focal mass suggestive of hepatoma and/or ascites.
  • For subjects with a history of diabetes or hypertension, clearance from an ophthalmologist has to be obtained prior to treatment start.

Exclusion criteria

Exclusion Criteria:

  • Subject is a female who is pregnant or breastfeeding, or who intends to become pregnant during the study.
  • Subject has used any product within 30 days prior to enrollment or is currently involved in another clinical trial.
  • Subjects weighing over 125 kg.
  • Subject has any of the following causes for the liver disease based on subject history or (where applicable) other than chronic , including but not limited to:

    • Hemochromatosis
    • Alpha-1 antitrypsin deficiency
    • Wilson's disease
    • hepatitis
    • Alcoholic liver disease
    • Non-alcoholic steatohepatitis (NASH)
    • Drug-related liver disease
  • Subject has any deviation from normal in the physical examination, chest x-ray, or (ECG) that, in the investigator's judgment, may interfere with the study evaluation or affect subject safety.
  • Subject is in a situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
  • Subject is part of the staff or a family member of the staff personnel directly involved with this study.
  • Subject is a previously untreated subject.
  • Subject has been treated with Pegasys + less than 1000 mg of ribavirin (instead of with 1000-1200 mg of ribavirin).
  • Subject has been discontinued from Pegasys treatment at any week due to an adverse event.
  • Subject is co-infected with (HIV) and/or virus (HBV).
  • Subject is suspected to be hypersensitive to interferon alpha or Peg-Intron or ribavirin.
  • Subject has previously received interferon, (except for the Pegasys flat dose 180 mcg QW for at least 12 weeks), thymosin or Cell Cept treatment or any other drug intended to treat chronic hepatitis C.
  • Subject has had organ transplants other than cornea and hair transplant.
  • Subject has a history of hepatocellular carcinoma or any other (except basal cell carcinoma) within the last 5 years or a suspected diagnosis of hepatocellular carcinoma or other malignancy, or an active malignancy.
  • Known coagulation diseases such as hemophilia; diseases (e.g. thalassemia).
  • Subject has glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • Subject has an evidence of decompensated liver disease such as history or presence of ascites, bleeding varices, spontaneous encephalopathy.
  • Subject has any known pre-existing medical condition that could interfere with the subject's participation in and completion of the study as followed below:

    • Preexisting psychiatric condition, especially moderate to severe depression, or a history of severe psychiatric disorder, such as psychosis, suicidal ideation, or suicide attempts. Severe depression includes the following:

      • Hospitalization for depression
      • Electroconvulsive therapy for depression, or
      • Depression causing a prolonged absence from work or significantly altering daily functions.
  • Subjects with mild depression may be considered for entry into the study provided that a pre-treatment assessment demonstrates that the subject's emotional status is clinically stable, in which case a management plan must be formulated for the subject; this management plan will become a part of the subject's medical record.

    • Craniocerebral trauma, which is not a concussion, or active seizure disorders requiring medication.
    • Clinically significant ECG abnormalities and/or cardiovascular dysfunction within 6 previous months (e.g., angina, congestive heart failure, recent myocardial infarction, or significant arrhythmia).
    • Chronic lung disease (e.g., chronic obstructive lung disease)
    • Poorly controlled diabetes mellitus: more than or equal to 8.5%
    • Immune-mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis)
    • Clinical gout
    • less than or equal to 50 mL/min
    • any medical condition which may require use of chronic systemic
  • Subject is or was a substance abuser, such as alcohol (80 g/day or more), methadone, intravenous (IV), oral or inhaled drugs. To be considered for inclusion, the subject must have abstained and agree to abstain from using any of the above for at least 6 months. Subjects treated with buprenorphine (Subutex) who have been stable for 6 months may be included.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    PegIntron plus Rebetol

    PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks

    Biological: PegIntron (peginterferon alfa-2b) · Drug: Rebetol (ribavirin)

Interventions

  • Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks

    Also known as: SCH 54031, PEG-Intron, PegIntron, ViraferonPeg, peginterferon alfa-2b

  • 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks

    Also known as: SCH 18908, Rebetol, REBETOL, ribavirin

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment

    Sustained virologic response is defined as a plasma HCV RNA level below Lower Level of Quantitation at 24 weeks post-treatment, which is \< 30 IU/mL in this study.

    Time frame: Up to 48 weeks of treatment plus 24 weeks follow up

07

Results

Posted Aug 4, 2009
Limitations and caveats
Due to slow enrollment, an unplanned interim analysis was conducted: 75 of 93 (80.6%) subjects who had reached treatment Week 12 did not achieve early virologic response. Given the low likelihood of response, a decision was made to stop enrollment.

Participant flow

Participant flow — Overall Study
MilestonePegIntron Plus Rebetol
Started117
Completed12
Not completed105
Withdrew: Lack of efficacy79
Withdrew: Withdrawal by subject8
Withdrew: Adverse event6
Withdrew: Protocol violation5
Withdrew: Lost to follow-up4
Withdrew: Failure to meet eligibility criteria3

Outcome measures

PrimaryNumber of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment

Sustained virologic response is defined as a plasma HCV RNA level below Lower Level of Quantitation at 24 weeks post-treatment, which is \< 30 IU/mL in this study.

Time frame:
Up to 48 weeks of treatment plus 24 weeks follow up
Reported as:
Number · Participants
Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment
ParticipantsPegIntron Plus Rebetol
Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PegIntron Plus REBETOL—6/117 (5.1%)105/117 (89.7%)
Most frequent serious events
Most frequent serious events
EventPegIntron Plus REBETOL
MENINGITIS ASEPTICInfections and infestations1/117
PELVIC FRACTUREInjury, poisoning and procedural complications1/117
WRIST FRACTUREInjury, poisoning and procedural complications1/117
DEHYDRATIONMetabolism and nutrition disorders1/117
HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/117
INTENTION TREMORNervous system disorders1/117
PRESYNCOPENervous system disorders1/117
DEPRESSIONPsychiatric disorders1/117
PSEUDODEMENTIAPsychiatric disorders1/117
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPegIntron Plus REBETOL
FATIGUEGeneral disorders33/117
ASTHENIAGeneral disorders29/117
HEADACHENervous system disorders29/117
INFLUENZA LIKE ILLNESSGeneral disorders25/117
PYREXIAGeneral disorders23/117
COUGHRespiratory, thoracic and mediastinal disorders21/117
MYALGIAMusculoskeletal and connective tissue disorders18/117
PRURITUSSkin and subcutaneous tissue disorders18/117
NAUSEAGastrointestinal disorders17/117
INFLUENZAInfections and infestations17/117

Baseline characteristics

Age, Continuous
Age, Continuous(years)PegIntron Plus Rebetol
Mean48.54 ± 11.02
Sex: Female, Male
Sex: Female, Male(Participants)PegIntron Plus Rebetol
Female35
Male82
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2007
First posted
Mar 1, 2007
Start
Jul 2005
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Aug 4, 2009
Last update
Apr 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00441584
Collaborators
Integrated Therapeutics Group
Responsible party
Sponsor
First posted
Mar 1, 2007
Start date
Jul 2005
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Aug 4, 2009
Last update
Apr 5, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion